Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | |
| Cash Flows From Operating Activities | ||||
| Net Income | 102 | 19,411 | 13,812 | 7,272 |
| Depreciation Amortization | 167 | 603 | 445 | 266 |
| Accounts receivable | 2,236 | N/A | -814 | 4,092 |
| Accounts payable and accrued liabilities | 112 | N/A | -1,663 | -50 |
| Other Working Capital | 557 | -7,536 | -12,281 | -7,225 |
| Other Operating Activity | -1,239 | 2,678 | 4,016 | -3,031 |
| Operating Cash Flow | $1,935 | $15,156 | $3,515 | $1,324 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -509 | -1,547 | -1,344 | -870 |
| Purchase Of Investment | 371 | N/A | N/A | N/A |
| Investing Cash Flow | $-138 | $-1,547 | $-1,344 | $-870 |
| Cash Flows From Financing Activities | ||||
| Debt Issued | N/A | N/A | 4,082 | 4,082 |
| Debt Repayment | N/A | N/A | -1,310 | N/A |
| Common Stock Issued | 187 | N/A | 108 | 13 |
| Other Financing Activity | 0 | 122,607 | 0 | 0 |
| Financing Cash Flow | $187 | $122,607 | $2,880 | $4,095 |
| Exchange Rate Effect | 481 | -587 | -13 | 283 |
| Beginning Cash Position | 166,119 | 30,490 | 30,490 | 30,490 |
| End Cash Position | 168,584 | 166,119 | 35,528 | 35,322 |
| Net Cash Flow | $2,465 | $135,629 | $5,038 | $4,832 |
| Free Cash Flow | ||||
| Operating Cash Flow | 1,935 | 15,156 | 3,515 | 1,324 |
| Capital Expenditure | -509 | N/A | -1,344 | -870 |
| Free Cash Flow | 1,426 | 15,156 | 2,171 | 454 |